Chr Hansen Holding A/S (CHRH)

553.4
-0.4(-0.07%)
  • Volume:
    12,429
  • Bid/Ask:
    0.0/0.0
  • Day's Range:
    550.6 - 554.8
  • Type:Equity
  • Market:Denmark
  • ISIN:DK0060227585
  • S/N:131852496

CHRH Overview

Prev. Close
553.8
Day's Range
550.6-554.8
Revenue
13.05B
Open
552.6
52 wk Range
504-730.2
EPS
11.37
Volume
12,429
Market Cap
72.88B
Dividend (Yield)
6.54
(0.00%)
Average Vol. (3m)
257,680
P/E Ratio
48.71
Beta
0.55
1-Year Change
-23.15%
Shares Outstanding
131,686,267
Next Earnings Date
Oct 14, 2021
What is your sentiment on Chr Hansen Holding A/S?
or
Vote to see community's results!

Chr Hansen Holding A/S News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellSellSellSell
Technical IndicatorsStrong SellStrong SellBuyBuyStrong Sell
SummaryStrong SellStrong SellNeutralNeutralStrong Sell

Chr Hansen Holding A/S Company Profile

Chr Hansen Holding A/S Company Profile

Employees
3600
Market
Denmark

Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. It operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry. The Health & Nutrition segment produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula, animal feed, and plant protection industries. The company was founded in 1874 and is headquartered in Hørsholm, Denmark.

Read More
  • strong company ... inviting and expanding ... always strong sales in Q1.. target next months 730
    0
    • target 700 next months
      0
      • Solid momentum continues: 9% organic growth in the first 6 months of 2018/19
        0
        • Solid organic revenue growth of 9% in the first half of 2018/19: Food Cultures & Enzymes 10%, Health & Nutrition 11% and Natural Colors 5%. EBIT before special items increased by 10% to EUR 150 million, corresponding to an EBIT margin before special items of 27.0% up 0.8%-point compared to last year. In Q2, organic growth was 8%, and EBIT before special items increased by 11%. The overall outlook for 2018/19 remains unchanged.
          0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.